- Home
- VRDN vs TVTX Comparison
VRDN vs TVTX Comparison
Compare VRDN & TVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VRDN
- TVTX
- Stock Information
- Founded
- VRDN 2006
- TVTX 2008
- Country
- VRDN United States
- TVTX United States
- Employees
- VRDN N/A
- TVTX N/A
- Industry
- VRDN Medical Specialities
- TVTX Biotechnology: Pharmaceutical Preparations
- Sector
- VRDN Health Care
- TVTX Health Care
- Exchange
- VRDN Nasdaq
- TVTX Nasdaq
- Market Cap
- VRDN 1.5B
- TVTX 1.5B
- IPO Year
- VRDN N/A
- TVTX N/A
- Fundamental
- Price
- VRDN $18.72
- TVTX $21.64
- Analyst Decision
- VRDN Strong Buy
- TVTX Strong Buy
- Analyst Count
- VRDN 11
- TVTX 16
- Target Price
- VRDN $38.80
- TVTX $34.53
- AVG Volume (30 Days)
- VRDN 894.1K
- TVTX 1.9M
- Earning Date
- VRDN 08-06-2025
- TVTX 10-30-2025
- Dividend Yield
- VRDN N/A
- TVTX N/A
- EPS Growth
- VRDN N/A
- TVTX N/A
- EPS
- VRDN N/A
- TVTX N/A
- Revenue
- VRDN $305,000.00
- TVTX $333,865,000.00
- Revenue This Year
- VRDN N/A
- TVTX $83.26
- Revenue Next Year
- VRDN $35,092.81
- TVTX $43.19
- P/E Ratio
- VRDN N/A
- TVTX N/A
- Revenue Growth
- VRDN 5.90
- TVTX 87.94
- 52 Week Low
- VRDN $9.90
- TVTX $9.44
- 52 Week High
- VRDN $27.20
- TVTX $25.29
- Technical
- Relative Strength Index (RSI)
- VRDN 55.80
- TVTX 78.22
- Support Level
- VRDN $18.12
- TVTX $17.27
- Resistance Level
- VRDN $20.05
- TVTX $19.57
- Average True Range (ATR)
- VRDN 1.02
- TVTX 0.99
- MACD
- VRDN -0.02
- TVTX 0.33
- Stochastic Oscillator
- VRDN 55.81
- TVTX 88.44
About VRDN Viridian Therapeutics Inc.
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate includes Veligrotug (formerly known as VRDN-001) for intravenous (IV) and VRDN-003 for subcutaneous (SC) administration. Veligrotug is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of thyroid eye disease (TED).
About TVTX Travere Therapeutics Inc.
Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN)-rare kidney disorders that often cause end-stage kidney disease.